Compare AKAM & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKAM | ASND |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 15.2B |
| IPO Year | 1999 | 2014 |
| Metric | AKAM | ASND |
|---|---|---|
| Price | $119.38 | $249.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $107.87 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 3.4M | 482.6K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $2,502,996,000.00 | N/A |
| Revenue This Year | $8.53 | $96.35 |
| Revenue Next Year | $7.09 | $44.91 |
| P/E Ratio | $172.21 | ★ N/A |
| Revenue Growth | ★ 6.96 | N/A |
| 52 Week Low | $69.79 | $175.19 |
| 52 Week High | $165.45 | $282.15 |
| Indicator | AKAM | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 42.88 |
| Support Level | $108.21 | $215.18 |
| Resistance Level | $131.08 | $249.89 |
| Average True Range (ATR) | 5.07 | 7.04 |
| MACD | 0.82 | -2.15 |
| Stochastic Oscillator | 52.68 | 25.30 |
Akamai operates a content delivery network, in which customers store content on distributed servers to deliver it to their own customers more quickly. Akamai has over 350,000 servers distributed over 4,350 points of presence in more than 700 cities globally. This network supports upward of 20% of global internet traffic, generating massive amounts of data. Using data generated by the delivery network, the firm offers cybersecurity products and cloud computing services, ranging from API security to zero-trust enterprise access, which has surpassed the delivery network in revenue and importance. As of 2026, the primary focus has shifted to offering computing hardware as a service, with an emphasis on serving large language model providers such as Anthropic.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.